Compare GOSS & PGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GOSS | PGP |
|---|---|---|
| Founded | 2015 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 101.2M | 102.9M |
| IPO Year | 2018 | N/A |
| Metric | GOSS | PGP |
|---|---|---|
| Price | $0.40 | $8.16 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $4.19 | N/A |
| AVG Volume (30 Days) | ★ 26.2M | 43.4K |
| Earning Date | 03-17-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.84% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $48,471,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $203.01 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.33 | $6.56 |
| 52 Week High | $3.87 | $9.41 |
| Indicator | GOSS | PGP |
|---|---|---|
| Relative Strength Index (RSI) | 23.42 | 19.64 |
| Support Level | $0.33 | $8.03 |
| Resistance Level | $0.60 | $8.26 |
| Average True Range (ATR) | 0.06 | 0.21 |
| MACD | 0.06 | -0.06 |
| Stochastic Oscillator | 0.00 | 6.43 |
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
PIMCO Global Stocksplus & Income Fund is a closed-end management investment company. The objective of the fund is to seek a total return comprised of current income, current gains, and long-term capital appreciation. The fund invests a majority of the fund's net assets in a combination of securities and instruments that provide exposure to stocks and or produce income.